Wegovy-Maker Novo Faces Calls to Map Out Strategy Beyond Weight-Loss Drugs

Wegovy-Maker Novo Faces Calls to Map Out Strategy Beyond Weight-Loss Drugs

## The Company That Changed How America Thinks About Weight Loss Just Got a Brutal Wake-Up Call From Its Own Investors

---

### The Day the Miracle Drug Wasn't Enough

Let me take you to London on Monday, September 21, 2026. Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy, the company that turned weight loss into a global obsession — held its first Capital Markets Day under new CEO Mike Doustdar.

This was supposed to be the moment Novo reassured the world. The moment it showed investors it had a plan. The moment it proved that the company that pioneered the obesity drug revolution could survive the coming patent cliff, the rising competition, and the slowing sales.

Instead, the stock **crashed**.

Shares fell as much as **9%** in Copenhagen trading before paring losses to around 5% by midday. The company laid out its 2030 strategy, and Wall Street wasn't buying it.

"Investors hoped for a project 'miracle' that could turn the momentum around short term," said Per Hansen, savings economist at Nordnet. "For obvious reasons that miracle does not exist".

This is the story of a company at a crossroads. A company that built a $600 billion empire on a single drug, and now has to figure out what comes next. A company that America knows as the maker of the weight-loss shot that changed everything — and that is now fighting for its life.

---

## The Elephant in the Room: Semaglutide's Patent Cliff

### The Drug That Built an Empire

Semaglutide is the active ingredient in Ozempic and Wegovy. It's the drug that made Novo Nordisk a household name. It's the drug that turned obesity from a personal struggle into a medical condition. It's the drug that generated billions of dollars in revenue and made Novo the most valuable company in Europe.

But semaglutide's patent protection is running out.

CEO Mike Doustdar didn't mince words. He told investors that the **"elephant in the room"** is that semaglutide will begin losing patent exclusivity in the early 2030s, starting in the U.S. in **2032** — a market that accounted for more than half of Novo's sales last year.

"We plan to come on the other side of the LOE as a bigger company than we are today and a much more diversified version of it," Doustdar said.

LOE stands for "loss of exclusivity." It's the pharmaceutical industry's version of a death sentence. When a drug goes off-patent, generic competitors flood the market with cheaper versions, and the original manufacturer's revenue collapses.

For Novo, the clock is ticking.

### The Generics Are Already Coming

And it's not just a future problem. Semaglutide has already lost exclusivity in **Canada, India, Brazil, and Turkey** this year, enabling generic competitors to launch much cheaper alternatives.

Sales are expected to **fall by up to 6% this year**. And analysts expect semaglutide to still represent **59% of Novo's sales in 2031**, according to Morgan Stanley — meaning the company is dangerously dependent on a drug that's about to face generic competition.

"Novo is in trouble," said one previously long-term investor who recently sold their fund's stake in the company. "They need something to replace semaglutide just to stand still".

---

## The Competition Problem: Eli Lilly Is Eating Novo's Lunch

### The Market Share Collapse

For years, Novo Nordisk and Eli Lilly were the two giants of the obesity drug market. Together, they controlled nearly 97% of global weight-loss drug sales.

But the balance of power has shifted dramatically. In the second quarter of 2026, **Lilly held a 60.9% share of the U.S. obesity and diabetes drug market, compared with Novo's 38.8%**, according to Lilly's earnings presentation.

Read that again. Lilly has nearly **two-thirds** of the market. Novo has barely more than a third.

Lilly's Zepbound and Mounjaro have become the dominant obesity drugs in America. Sales of Zepbound are expected to **outpace Wegovy by more than $7 billion this year**, according to LSEG data.

### The Stock Price Divergence

The market has noticed. Novo's share price has **plunged by more than 70% since its peak**. Over the past 12 months, Novo stock had shed **27%** heading into Monday's session. Eli Lilly's stock, by contrast, has **gained 52%** over the same period.

One company is winning. The other is losing. And the gap is widening.

---

## The 2030 Strategy: What Novo Actually Announced

### The Headline Targets

At the Capital Markets Day, Doustdar laid out Novo's plan to revive growth. Here's what the company promised:

**More than five "multi-blockbuster" drugs by 2030.** These are drugs with the potential to generate massive sales across multiple indications.

**More than 150 billion Danish kroner ($23 billion) in pipeline sales by 2035.** This is the revenue Novo expects from drugs currently in development.

**Revenue growth in line with industry peers from 2026 to 2030.** This is a deliberately vague target — and analysts noticed.

**Scaling oral GLP-1 manufacturing tenfold.** Novo wants to supply **15 million patients** with oral obesity therapies by the end of the decade.

**Reaching more than 60 million patients globally by 2030**.

### The Diversification Push

The most important part of the strategy is diversification. Novo wants to expand beyond obesity and diabetes into:

**Cardiovascular disease.** Novo has a partnership with Orbis Medicines worth up to **$1.4 billion** to develop next-generation oral macrocycle therapies for cardiometabolic diseases.

**Liver disease.** Novo is developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a liver condition linked to obesity.

**Blood and endocrine disorders.** These are new therapeutic areas for Novo, representing a significant expansion of its focus.

**Rare diseases.** Novo already has a presence in rare blood disorders, and it's looking to expand.

Doustdar said the company "will be more active within business development" — a signal that more acquisitions are coming.

### The Pipeline: CagriSema and Zenagamtide

The centerpiece of Novo's pipeline is **CagriSema**, a combination therapy that pairs semaglutide with cagrilintide. Novo plans to launch CagriSema in **early 2027**, followed by standalone cagrilintide and high-dose CagriSema in 2028.

But here's where it gets interesting. Some analysts think Novo should pivot away from CagriSema and focus on **zenagamtide** instead.

Morningstar analyst Karen Andersen said Novo should focus more on promising early-pipeline candidate zenagamtide, rather than continuing to pour money into CagriSema.

Zenagamtide is a next-generation unimolecular GLP-1 and amylin receptor agonist in Phase 3 development for obesity and diabetes. Novo has launched various Phase 3 studies of zenagamtide for obesity and related conditions, including sleep apnea and knee osteoarthritis.

The company expects to launch zenagamtide "soon after" CagriSema, according to Doustdar.

---

## Why Investors Aren't Buying It

### The "Miracle" That Doesn't Exist

The problem with Novo's strategy isn't that it's bad. It's that it's **not good enough**.

Investors wanted a transformative announcement. They wanted a game-changer. They wanted something that would immediately reverse Novo's fortunes and close the gap with Eli Lilly.

What they got was a plan to grow "in line with industry peers" — a target that signals ambition well below what the market has long assumed Novo capable of delivering.

"The investors, they are very particular in what they want from Novo, and this doesn't add up to it," said Jacob Pedersen, investment strategist at Danish bank Middelfart Sparekasse.

Per Hansen of Nordnet put it even more bluntly: "Investors hoped for a project 'miracle' that could turn the momentum around short term. For obvious reasons that miracle does not exist".

### The Missing M&A Strategy

Shareholders have been calling for Novo to pursue **large-scale acquisitions** to diversify its portfolio and reduce its reliance on semaglutide.

Eugen Uretzki, an investment analyst at top 15 shareholder Flossbach, said there were "two jobs for a chief executive: you have to develop the assets and commercialise them." He said the "development of assets is still to be proven," adding this was "urgent given the competition from Lilly".

Julia Angeles, investment manager at shareholder Baillie Gifford, said Novo needed to "lay out what the transition from Ozempic looks like," including by pursuing partnerships that would allow it to explore experimental treatments before fully committing to them.

"I would like to see Novo put their tentacles in as many novel approaches as possible," she said. "You cannot do M&A without a clear strategy".

But here's the catch: **Novo has said it's not currently in a position to pursue large-scale M&A**. CEO Doustdar ruled out any large transformative deals in August, saying the company would focus on bolt-on acquisitions instead.

That's a problem. Shareholders want big deals. Novo says it can't afford them. And the clock is ticking.

---

## The Human Cost: 13,000 Jobs Gone

### The Restructuring

Behind the strategy and the stock prices and the pipeline updates, there are people. And for Novo, those people are paying the price for the company's struggles.

Total departures linked to Novo's corporate restructuring have reached **13,000 employees**, following an initial round of 9,000 cuts and an additional 4,000 subsequent exits.

Thirteen thousand people. That's not a rounding error. That's a city's worth of workers who lost their jobs because Novo bet too heavily on one drug and got caught flat-footed by the competition.

### The Rebrand

And then there's the rebrand. Novo Nordisk is now just **"Novo."** The company ditched "Nordisk" from its name and promised a cultural reset dubbed **"The Novo Way"** .

At a town-hall meeting in Copenhagen, Doustdar told employees this meant being more consumer-focused. The company is trying to position itself as a modern, agile player in a market it once dominated.

But rebranding doesn't change the fundamentals. It doesn't replace lost revenue. It doesn't develop new drugs. It doesn't win back market share from Eli Lilly.

It's a fresh coat of paint on a house that needs a new foundation.

---

## The Oral GLP-1 Advantage: Novo's One Bright Spot

### The Wegovy Pill

There is one area where Novo leads the market: **oral GLP-1 drugs**.

Novo launched the Wegovy pill in the U.S. at the beginning of 2026, and it's been a success. The pill has achieved a record **7 million prescriptions in the U.S. to date**, with **90% of those sales flowing through direct cash-pay channels**.

As of September 11, the Wegovy pill exceeded **161,065 weekly prescriptions** — more than **three times the level of Lilly's** oral obesity drug, according to data provider IQVIA.

This is a genuine competitive advantage. Oral GLP-1 drugs are easier to manufacture, easier to distribute, and easier for patients to take. They don't require refrigeration. They don't require injections. And they can be produced at scale.

Novo plans to scale oral GLP-1 manufacturing capacity **tenfold** to supply **15 million patients** by the end of the decade. The company is also accelerating its portfolio of pills, aiming to have at least **five oral assets in clinical trials** before the end of this year.

### Why Oral Matters

The obesity drug market is shifting from injectables to oral therapies. Injectables are effective, but they're expensive, inconvenient, and require cold-chain logistics. Oral drugs are cheaper, easier to take, and more scalable.

If Novo can maintain its lead in oral GLP-1s, it has a path to growth that doesn't depend on semaglutide. But the competition is coming. Lilly is developing its own oral obesity drugs. So are other companies.

The window of opportunity is narrowing.

---

## The Financial Reality: What the Numbers Say

### The Sales Decline

Novo disclosed in August that it anticipates adjusted sales and adjusted operating profit each **declining somewhere in a range from 6% to flat** for full-year 2026, measured at constant exchange rates.

That's not growth. That's contraction. And it's happening while Eli Lilly is posting surging sales and raising guidance.

### The Analyst Ratings

Analysts are cautious. According to 14 analysts polled by S&P Global, Novo Nordisk stock has a consensus rating of **"Hold"** and an average price target of **$47.22**.

**BMO Capital** maintained a Hold rating with a **$47 price target**.

**UBS** maintained a Hold rating with a price target of **DKK 332**.

**Morgan Stanley** retained a **$40 price target** but raised concerns that Novo's valuation does not fully reflect muted medium-term growth and the longer-term risk from the semaglutide patent cliff.

**Deutsche Bank** maintained a **Sell rating**.

The message from the analyst community is clear: Novo is a "show me" story. The market wants to see results, not promises.

---

## Frequently Asked Questions (FAQs)

### Q1: Why are investors pressuring Novo Nordisk?

Investors are pressuring Novo Nordisk to develop new medicines and pursue acquisitions to reduce its reliance on blockbuster weight-loss treatments. The company generates more than 90% of its sales from diabetes and obesity treatments, and its key drug semaglutide faces patent expiries in the early 2030s.

### Q2: What is the "patent cliff" and why does it matter?

The patent cliff refers to the expiration of patent protection for semaglutide — the active ingredient in Ozempic and Wegovy — starting in the early 2030s. When patents expire, generic competitors can launch cheaper versions, causing revenue to collapse. Novo's semaglutide patents expire in the U.S. in 2032.

### Q3: How is Eli Lilly beating Novo Nordisk?

Eli Lilly has captured a majority share of the obesity drug market with its Zepbound and Mounjaro treatments. In the second quarter of 2026, Lilly held 60.9% of the U.S. obesity and diabetes drug market, compared with Novo's 38.8%.

### Q4: What is Novo's 2030 strategy?

Novo aims to launch more than five "multi-blockbuster" drugs by 2030, generate more than $23 billion in pipeline sales by 2035, scale oral GLP-1 manufacturing tenfold, and reach more than 60 million patients globally. The company is diversifying into cardiovascular disease, liver disease, and blood and endocrine disorders.

### Q5: What is CagriSema?

CagriSema is a combination therapy that pairs semaglutide with cagrilintide. Novo plans to launch it in early 2027, followed by standalone cagrilintide and high-dose CagriSema in 2028. Some analysts believe Novo should focus on zenagamtide instead.

### Q6: What is zenagamtide?

Zenagamtide is a next-generation unimolecular GLP-1 and amylin receptor agonist in Phase 3 development for obesity and diabetes. Some analysts believe it's a more promising candidate than CagriSema.

### Q7: Why did Novo's stock fall after the Capital Markets Day?

Novo's stock fell because investors were disappointed with the company's growth targets. The plan to grow "in line with industry peers" signals ambition well below what the market expected. Investors wanted a transformative announcement, and they didn't get one.

### Q8: What is "The Novo Way"?

"The Novo Way" is a cultural reset announced by CEO Mike Doustdar. It's part of a rebrand that dropped "Nordisk" from the company's name. The goal is to make the company more consumer-focused.

### Q9: How many jobs has Novo cut?

Total departures linked to Novo's restructuring have reached 13,000 employees, following an initial round of 9,000 cuts and an additional 4,000 subsequent exits.

### Q10: What is the Wegovy pill?

The Wegovy pill is an oral version of Novo's weight-loss drug. It launched in the U.S. in early 2026 and has achieved a record 7 million prescriptions. It leads the market for oral obesity drugs, with more than three times the weekly prescriptions of Lilly's oral drug.

### Q11: What acquisitions has Novo made?

Novo has partnered with Orbis Medicines in a deal worth up to $1.4 billion to develop oral macrocycle therapies for cardiometabolic diseases. It has also acquired three early-stage obesity drug programs from Kallyope.

### Q12: Will Novo pursue large-scale M&A?

CEO Mike Doustdar has ruled out large transformative deals, saying the company is not currently in a position to pursue them. Novo will focus on bolt-on acquisitions instead.

### Q13: What is Novo's dividend and buyback policy?

This article does not contain specific dividend or buyback information. Readers should consult Novo's investor relations website for the most current information.

### Q14: Is Novo Nordisk a good investment?

That's a personal decision that depends on your financial situation, risk tolerance, and investment goals. This article is not financial advice. Consult a qualified financial advisor before making any investment decisions.

### Q15: What's the bottom line?

Novo Nordisk is at a crossroads. It built an empire on semaglutide, and now it has to figure out what comes next. The competition from Eli Lilly is intensifying, the patent cliff is approaching, and investors are losing patience. Novo has a plan, but the market isn't convinced it's enough.

---

## High-Value Keywords and Tags for AdSense Optimization

**Primary Keywords:**

- Novo Nordisk strategy beyond weight loss

- Novo Nordisk investor pressure 2026

- Wegovy maker growth strategy

- Novo Nordisk Capital Markets Day

- Semaglutide patent cliff

**High-Value Financial Keywords:**

- Novo Nordisk stock analysis 2026

- NVO stock price target

- Best pharma stocks 2026

- Eli Lilly vs Novo Nordisk

- Obesity drug market share

**Long-Tail Keywords (Low Competition, High Intent):**

- What is Novo Nordisk's 2030 strategy

- Why did Novo Nordisk stock fall

- Novo Nordisk vs Eli Lilly obesity drugs

- Semaglutide patent expiry impact

- Novo Nordisk pipeline 2026

- Best obesity drug stocks 2026

- Novo Nordisk M&A strategy

**Tags:**

#NovoNordisk #Wegovy #Ozempic #Semaglutide #EliLilly #Zepbound #ObesityDrugs #GLP1 #PharmaNews #StockMarket #Investing #NVO #LLY #PatentCliff #CagriSema #Zenagamtide #HealthcareInvesting #Biotech #Pharmaceuticals #MarketNews #FinancialNews #BusinessNews #WeightLossDrugs #DiabetesDrugs #CapitalMarketsDay #MikeDoustdar #DrugPipeline #MergersAndAcquisitions #AmericanInvestor #MarketAnalysis

---

## Conclusion: The Empire Built on One Drug

Novo Nordisk is a company that changed the world. It turned obesity from a personal failing into a medical condition. It gave millions of Americans a tool to lose weight and improve their health. It built a $600 billion empire on the back of a single drug.

But that empire is now under siege. The patent cliff is coming. Eli Lilly is winning. Investors are losing patience. And the strategy that Novo laid out on Monday — a plan to diversify, to develop new drugs, to grow "in line with peers" — wasn't enough to calm the market's nerves.

The company is cutting jobs. It's rebranding. It's making deals. It's betting on oral GLP-1s and a pipeline of next-generation obesity drugs. It's trying to build a future that doesn't depend on semaglutide.

But the clock is ticking. The generics are coming. The competition is fierce. And the market is watching.

Novo has one advantage that no competitor can replicate: it's the company that started this revolution. It has the science, the manufacturing capacity, and the brand recognition. It has the Wegovy pill, which leads the oral obesity market. It has a pipeline that includes CagriSema, zenagamtide, and promising early-stage assets.

Whether that's enough to survive the coming storm is the question that will define Novo's next decade. And the answer isn't clear yet.

"Novo is in trouble," the former long-term investor said. "They need something to replace semaglutide just to stand still".

The company knows this. The question is whether it can move fast enough to do something about it.

---

## Disclaimer

This article is for informational and educational purposes only and does not constitute financial, investment, or legal advice. The views expressed are those of the author and do not necessarily reflect the official policy or position of any financial institution. Investing involves risk, including the possible loss of principal. Past performance does not guarantee future results. Readers should consult with a qualified financial advisor before making any investment decisions. The author is not responsible for any financial losses incurred as a result of actions taken based on the information provided in this article. All data and figures cited are sourced from publicly available reports and are subject to change.